Congo approves use of experimental Ebola drugs: 4 things to know

Listen
Text
  • Small
  • Medium
  • Large

The Democratic Republic of Congo's health ministry greenlighted four experimental Ebola treatments Aug. 22 amid the country's ongoing outbreak, according to Reuters

Here are four things to know:

1. The treatments include ZMapp, Remdesivir, Favipiravir and Regn3450-3471-3479.

2. Health officials previously approved used of the experimental medication mAb1which health official have administered to 10 patients since Aug. 11, according to a Congo's health ministry.

3. Since Aug. 8, about 1,600 people have received vaccines, although red zones, where outsiders may be banned from entering, are complicating treatment efforts.

4. This marks the Congo's tenth Ebola outbreak. So far, there are 75 confirmed Ebola cases and 27 unconfirmed cases. Fifty-nine deaths are linked to the outbreak, 32 of which were officially linked to Ebola, the health ministry said.

More articles on clincal leadership and infection control:

Some Hurricane Harvey victims still need help finding medical services, survey finds

CDC updates flu vaccine recommendations

Feinstein researcher wins $1.65M grant for sepsis research

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars